# CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

> **NCT03408873** · PHASE4 · COMPLETED · sponsor: **Martha Sajatovic** · enrollment: 30 (actual)

## Conditions studied

- Bipolar Disorder
- Medication Adherence
- Medication Non Adherence

## Interventions

- **DRUG:** Abilify Maintena
- **BEHAVIORAL:** Customized Adherence Enhancement (CAE)

## Key facts

- **NCT ID:** NCT03408873
- **Lead sponsor:** Martha Sajatovic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-01
- **Primary completion:** 2020-05-06
- **Final completion:** 2020-05-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03408873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03408873, "CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03408873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*